Review of 2008: Innovation in ICDs continues amid calls for more strenuous testing
This article was originally published in Clinica
Executive Summary
2008 was a tempestuous year for developers of implantable cardioverter defibrillators (ICDs), small battery-powered devices that detect cardiac arrhythmia and correct it by delivering an electric shock. The year started with ICD companies in a difficult position; October 2007 had seen the disastrous recall, amid safety concerns, of Medtronic's Sprint Fidelis ICD lead. Whilst Medtronic has recovered from this to a large degree, the sector in general has been buffeted by negative trial results and calls for more stringent regulation of the devices and their peripherals.
You may also be interested in...
Falling Sales Force New Priorities At Roche
The Swiss major brings a new ruthlessness to the compounds in its pipeline: if they’re not first or best, they’re out.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.
Normality Reasserts Itself For Biotech IPOs
The highs of the COVID-19 era, and the lows that supplanted it, are beginning to fade.